IBOV 177,547.57 ▲ 2.44% IPSA 11,009.22 ▲ 0.50% IPC MEX 67,298.78 ▲ 0.88% MERVAL 3,379,771 ▲ 2.98% COLCAP 2,297.00 ▼ 0.19% BVL PERÚ 57,575.02 — — USD/BRL5.05▼ 0.01% USD/MXN17.38▼ 0.09% USD/CLP937.27▲ 0.17% USD/COP3,205▼ 0.70% USD/PEN3.39▼ 0.30% USD/ARS1,482▼ 0.03% USD/UYU40.14▲ 1.16% USD/PYG6,035▲ 1.38% USD/BOB10.95▲ 2.82% USD/DOP57.99▼ 0.36% USD/CRC447.42▲ 1.36% USD/GTQ7.62▲ 2.27% USD/HNL26.74▲ 0.88% USD/NIO36.62▲ 0.31% USD/VES736.04▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.49▲ 0.36% USD/TTD6.71▲ 0.76% EUR/BRL5.78▼ 0.36% BRENT 95.91 ▲ 1.96% WTI 88.15 ▲ 1.52% IRON ORE 161.91 — — COPPER 6.53 ▲ 1.19% GOLD 4,126 ▼ 0.52% SILVER 60.03 ▲ 0.01% SOY 1,242 ▲ 0.69% CORN 485.00 ▲ 4.98% WHEAT 704.00 ▼ 0.25% COFFEE 318.05 ▼ 4.19% SUGAR 14.75 ▼ 0.87% ORANGE JUICE 147.50 ▲ 2.57% COTTON 81.36 ▲ 3.04% COCOA 5,353 ▼ 4.53% BEEF 219.20 ▼ 3.30% CATTLE 336.15 ▼ 3.83% LITHIUM 69.00 ▼ 0.12% PETR4 42.58 ▲ 2.21% VALE3 75.10 ▲ 3.77% ITUB4 42.90 ▲ 0.87% BBDC4 18.97 ▲ 2.26% ABEV3 16.13 ▲ 2.09% BBAS3 21.09 ▲ 1.01% B3SA3 15.90 ▲ 4.81% WEGE3 46.74 ▲ 10.05% PRIO3 59.77 ▲ 2.73% SUZB3 42.66 ▲ 2.47% RENT3 37.14 ▲ 1.61% AZZA3 17.81 ▲ 1.89% CSAN3 3.92 ▲ 3.70% RAIZ4 0.27 — 0.00% PCAR3 2.75 ▲ 0.73% GMAT3 3.91 ▲ 2.09% PSSA3 55.45 ▲ 3.68% CVCB3 1.27 ▲ 13.39% POSI3 3.70 ▲ 0.54% SLCE3 13.96 ▲ 1.53% NATU3 8.68 ▼ 0.34% BRKM5 6.07 ▲ 6.30% RANI3 8.00 ▲ 1.39% CSNA3 5.38 ▲ 6.32% CMIN3 5.84 ▲ 4.66% USIM5 8.65 ▲ 2.25% GGBR4 24.06 ▲ 2.43% ENEV3 25.97 ▲ 2.16% CPFE3 46.71 ▲ 0.67% CMIG4 11.21 ▲ 1.72% EQTL3 39.35 ▲ 1.34% LREN3 13.54 ▲ 2.03% VIVT3 35.38 ▼ 1.17% RAIL3 13.64 ▲ 3.02% KLABIN 17.93 ▲ 1.93% RAIA DROGASIL 18.29 ▲ 0.88% RDOR3 34.49 ▲ 1.68% HAPV3 11.39 ▲ 1.33% FLRY3 16.65 ▲ 0.60% SMTO3 16.05 ▲ 3.02% UGPA3 32.83 ▲ 3.17% VBBR3 34.98 ▲ 3.03% BBSE3 42.58 ▲ 2.48% BPAC11 57.02 ▲ 2.98% CURY3 30.20 ▲ 0.83% AERI3 2.05 ▲ 0.49% VIVARA 21.55 ▲ 0.65% COMPASS 24.81 ▲ 1.51% VAMOS 3.23 ▲ 4.53% SANB11 26.95 ▼ 0.96% ASAI3 8.40 ▲ 1.82% SBSP3 29.29 ▲ 2.41% WALMEX 48.65 ▼ 1.02% GMEXICO 214.34 ▲ 2.57% FEMSA 227.98 ▲ 0.55% CEMEX 22.17 ▲ 0.45% GFNORTE 191.99 ▲ 3.33% BIMBO 60.30 ▲ 1.53% TELEVISA 9.82 ▲ 0.61% AMX 22.70 ▼ 0.26% GAP 378.40 ▼ 0.03% ASUR 273.53 ▼ 0.52% OMA 229.62 ▲ 1.49% KOF 182.55 ▲ 1.15% GRUMA 280.45 ▼ 0.76% KIMBER 38.85 ▲ 1.17% SQM-B 65,055 ▲ 0.80% COPEC 6,550 ▲ 1.55% BSANTANDER 79.85 ▲ 1.06% FALABELLA 6,042 ▲ 2.08% ENELAM 84.53 — 0.00% CENCOSUD 2,010 ▼ 0.89% CMPC 1,070 ▼ 1.28% BANCO CHILE 193.50 ▲ 1.84% LATAM AIR 24.09 ▼ 0.45% YPF 82,500 ▲ 2.33% GGAL 8,275 ▲ 3.89% PAMPA 5,625 ▲ 2.74% TXAR 668.50 ▼ 1.55% ALUAR 974.00 ▲ 0.10% TGS 9,905 ▲ 2.01% CEPU 2,411 ▲ 3.03% MIRGOR 16,925 ▲ 0.89% COME 43.14 ▲ 0.63% LOMA NEGRA 3,823 ▲ 6.03% BYMA 295.00 ▲ 0.94% TELECOM ARG 4,420 ▲ 3.88% ECOPETROL 16.69 ▲ 0.97% BANCOLOMBIA 84.66 ▲ 1.22% GRUPO AVAL 5.04 ▼ 0.98% CREDICORP 393.43 ▲ 0.60% SOUTHERN COPPER 195.48 ▲ 3.97% BUENAVENTURA 32.09 ▲ 2.69% MERCADOLIBRE 1,799 ▼ 1.29% NUBANK 14.51 ▲ 0.83% XP 17.30 ▲ 2.67% PAGSEGURO 9.67 ▲ 0.94% STONE 11.36 ▲ 0.93% GLOBANT 30.67 ▼ 4.45% TECNOGLASS 45.24 ▲ 0.20% GAP AIRPORT 217.70 ▲ 0.01% ASUR 273.53 ▼ 0.52% OMA AIRPORT 105.35 ▲ 1.07% AMX ADR 26.12 ▲ 0.12% FEMSA ADR 130.96 ▲ 0.47% CEMEX ADR 12.74 ▲ 0.32% PETROBRAS ADR 18.89 ▲ 1.89% VALE ADR 14.85 ▲ 4.21% ITAU ADR 8.48 ▲ 0.95% SANTANDER BR 5.45 ▲ 0.74% AMBEV ADR 3.14 ▲ 0.96% CSN 1.09 ▲ 9.00% GERDAU 4.77 ▲ 2.69% LATAM ADR 51.22 ▼ 0.68% BTC 65,568 ▼ 0.81% ETH 1,918 ▼ 0.78% SOL 77.41 ▼ 0.64% XRP 1.13 ▼ 0.63% BNB 569.43 ▼ 0.23% ADA 0.17 — 0.00% DOGE 0.07 ▼ 0.63% AVAX 6.54 ▼ 1.16% LINK 8.58 ▼ 0.51% DOT 0.82 ▼ 1.22% LTC 47.16 ▲ 0.19% BCH 217.56 ▼ 1.09% TRX 0.33 ▼ 0.04% XLM 0.18 ▼ 1.57% HBAR 0.07 ▲ 0.56% NEAR 1.86 ▼ 0.27% ATOM 1.45 ▼ 0.99% AAVE 96.84 ▼ 0.53% SELIC 14.25% EMBRAER 83.79 ▲ 1.38% EMBRAER ADR 66.05 ▲ 0.89% JBS 12.25 ▲ 2.51% JBS BDR 61.80 ▲ 2.62% MBRF3 16.03 ▲ 6.09% MBRFY 3.19 ▲ 8.14% INTER 5.69 ▲ 1.97% IBOV 177,547.57 ▲ 2.44% IPSA 11,009.22 ▲ 0.50% IPC MEX 67,298.78 ▲ 0.88% MERVAL 3,379,771 ▲ 2.98% COLCAP 2,297.00 ▼ 0.19% BVL PERÚ 57,575.02 — — USD/BRL 5.05 ▼ 0.01% USD/MXN 17.38 ▼ 0.09% USD/CLP 937.27 ▲ 0.17% USD/COP 3,205 ▼ 1.57% USD/PEN 3.39 ▼ 0.30% USD/ARS 1,482 ▼ 0.03% USD/UYU 40.14 ▲ 1.16% USD/PYG 6,035 ▲ 1.38% USD/BOB 10.95 ▲ 3.79% USD/DOP 57.99 ▼ 0.02% USD/CRC 447.42 ▲ 1.35% USD/GTQ 7.62 ▲ 2.31% USD/HNL 26.74 ▲ 0.88% USD/NIO 36.62 ▲ 0.31% USD/VES 736.04 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.49 ▲ 0.36% USD/TTD 6.71 ▲ 0.76% EUR/BRL 5.78 ▼ 0.36% BRENT 95.91 ▲ 1.96% WTI 88.15 ▲ 1.52% IRON ORE 161.91 — — COPPER 6.53 ▲ 1.19% GOLD 4,126 ▼ 0.52% SILVER 60.03 ▲ 0.01% SOY 1,242 ▲ 0.69% CORN 485.00 ▲ 4.98% WHEAT 704.00 ▼ 0.25% COFFEE 318.05 ▼ 4.19% SUGAR 14.75 ▼ 0.87% ORANGE JUICE 147.50 ▲ 2.57% COTTON 81.36 ▲ 3.04% COCOA 5,353 ▼ 4.53% BEEF 219.20 ▼ 3.30% CATTLE 336.15 ▼ 3.83% LITHIUM 69.00 ▼ 0.12% PETR4 42.58 ▲ 2.21% VALE3 75.10 ▲ 3.77% ITUB4 42.90 ▲ 0.87% BBDC4 18.97 ▲ 2.26% ABEV3 16.13 ▲ 2.09% BBAS3 21.09 ▲ 1.01% B3SA3 15.90 ▲ 4.81% WEGE3 46.74 ▲ 10.05% PRIO3 59.77 ▲ 2.73% SUZB3 42.66 ▲ 2.47% RENT3 37.14 ▲ 1.61% AZZA3 17.81 ▲ 1.89% CSAN3 3.92 ▲ 3.70% RAIZ4 0.27 — 0.00% PCAR3 2.75 ▲ 0.73% GMAT3 3.91 ▲ 2.09% PSSA3 55.45 ▲ 3.68% CVCB3 1.27 ▲ 13.39% POSI3 3.70 ▲ 0.54% SLCE3 13.96 ▲ 1.53% NATU3 8.68 ▼ 0.34% BRKM5 6.07 ▲ 6.30% RANI3 8.00 ▲ 1.39% CSNA3 5.38 ▲ 6.32% CMIN3 5.84 ▲ 4.66% USIM5 8.65 ▲ 2.25% GGBR4 24.06 ▲ 2.43% ENEV3 25.97 ▲ 2.16% CPFE3 46.71 ▲ 0.67% CMIG4 11.21 ▲ 1.72% EQTL3 39.35 ▲ 1.34% LREN3 13.54 ▲ 2.03% VIVT3 35.38 ▼ 1.17% RAIL3 13.64 ▲ 3.02% KLABIN 17.93 ▲ 1.93% RAIA DROGASIL 18.29 ▲ 0.88% RDOR3 34.49 ▲ 1.68% HAPV3 11.39 ▲ 1.33% FLRY3 16.65 ▲ 0.60% SMTO3 16.05 ▲ 3.02% UGPA3 32.83 ▲ 3.17% VBBR3 34.98 ▲ 3.03% BBSE3 42.58 ▲ 2.48% BPAC11 57.02 ▲ 2.98% CURY3 30.20 ▲ 0.83% AERI3 2.05 ▲ 0.49% VIVARA 21.55 ▲ 0.65% COMPASS 24.81 ▲ 1.51% VAMOS 3.23 ▲ 4.53% SANB11 26.95 ▼ 0.96% ASAI3 8.40 ▲ 1.82% SBSP3 29.29 ▲ 2.41% WALMEX 48.65 ▼ 1.02% GMEXICO 214.34 ▲ 2.57% FEMSA 227.98 ▲ 0.55% CEMEX 22.17 ▲ 0.45% GFNORTE 191.99 ▲ 3.33% BIMBO 60.30 ▲ 1.53% TELEVISA 9.82 ▲ 0.61% AMX 22.70 ▼ 0.26% GAP 378.40 ▼ 0.03% ASUR 273.53 ▼ 0.52% OMA 229.62 ▲ 1.49% KOF 182.55 ▲ 1.15% GRUMA 280.45 ▼ 0.76% KIMBER 38.85 ▲ 1.17% SQM-B 65,055 ▲ 0.80% COPEC 6,550 ▲ 1.55% BSANTANDER 79.85 ▲ 1.06% FALABELLA 6,042 ▲ 2.08% ENELAM 84.53 — 0.00% CENCOSUD 2,010 ▼ 0.89% CMPC 1,070 ▼ 1.28% BANCO CHILE 193.50 ▲ 1.84% LATAM AIR 24.09 ▼ 0.45% YPF 82,500 ▲ 2.33% GGAL 8,275 ▲ 3.89% PAMPA 5,625 ▲ 2.74% TXAR 668.50 ▼ 1.55% ALUAR 974.00 ▲ 0.10% TGS 9,905 ▲ 2.01% CEPU 2,411 ▲ 3.03% MIRGOR 16,925 ▲ 0.89% COME 43.14 ▲ 0.63% LOMA NEGRA 3,823 ▲ 6.03% BYMA 295.00 ▲ 0.94% TELECOM ARG 4,420 ▲ 3.88% ECOPETROL 16.69 ▲ 0.97% BANCOLOMBIA 84.66 ▲ 1.22% GRUPO AVAL 5.04 ▼ 0.98% CREDICORP 393.43 ▲ 0.60% SOUTHERN COPPER 195.48 ▲ 3.97% BUENAVENTURA 32.09 ▲ 2.69% MERCADOLIBRE 1,799 ▼ 1.29% NUBANK 14.51 ▲ 0.83% XP 17.30 ▲ 2.67% PAGSEGURO 9.67 ▲ 0.94% STONE 11.36 ▲ 0.93% GLOBANT 30.67 ▼ 4.45% TECNOGLASS 45.24 ▲ 0.20% GAP AIRPORT 217.70 ▲ 0.01% ASUR 273.53 ▼ 0.52% OMA AIRPORT 105.35 ▲ 1.07% AMX ADR 26.12 ▲ 0.12% FEMSA ADR 130.96 ▲ 0.47% CEMEX ADR 12.74 ▲ 0.32% PETROBRAS ADR 18.89 ▲ 1.89% VALE ADR 14.85 ▲ 4.21% ITAU ADR 8.48 ▲ 0.95% SANTANDER BR 5.45 ▲ 0.74% AMBEV ADR 3.14 ▲ 0.96% CSN 1.09 ▲ 9.00% GERDAU 4.77 ▲ 2.69% LATAM ADR 51.22 ▼ 0.68% BTC 65,568 ▼ 0.81% ETH 1,918 ▼ 0.78% SOL 77.41 ▼ 0.64% XRP 1.13 ▼ 0.63% BNB 569.43 ▼ 0.23% ADA 0.17 — 0.00% DOGE 0.07 ▼ 0.63% AVAX 6.54 ▼ 1.16% LINK 8.58 ▼ 0.51% DOT 0.82 ▼ 1.22% LTC 47.16 ▲ 0.19% BCH 217.56 ▼ 1.09% TRX 0.33 ▼ 0.04% XLM 0.18 ▼ 1.57% HBAR 0.07 ▲ 0.56% NEAR 1.86 ▼ 0.27% ATOM 1.45 ▼ 0.99% AAVE 96.84 ▼ 0.53% SELIC 14.25% EMBRAER 83.79 ▲ 1.38% EMBRAER ADR 66.05 ▲ 0.89% JBS 12.25 ▲ 2.51% JBS BDR 61.80 ▲ 2.62% MBRF3 16.03 ▲ 6.09% MBRFY 3.19 ▲ 8.14% INTER 5.69 ▲ 1.97%
since 2009
Thursday, July 23, 2026

Cannabis market grows while omitting the risks of supposed medicinal use

By · February 21, 2023 · 6 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

Pro-marijuana movements have progressively expanded with the advance of technology.

On social networks, it is possible to find a series of profiles that deliberately and without any restriction promote the drug.

The trade of products based on the plant, with supposed medicinal effects, has also grown – a survey done by Kaya Mind, a Brazilian company specializing in data and market intelligence in the cannabis segment, showed that Brazil has more than 80 companies with CNPJ open that operate in this market, even without comprehensive regulation.

Websites and social networks of companies that sell cannabis-based products exaggerate benefits and omit risks of the substances (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

According to one of these companies, Remederi, the number of doctors prescribing the drug has recently increased by more than 250%, going from 200 prescribers in 2019 to more than 5,000 today.

Some websites indicate the step-by-step for those who wish to acquire the necessary prescription for cannabis products and that point out the possible health benefits of cannabidiol (CBD), one of the substances in the plant, but without mentioning the possible risks of marijuana to the body.

On the website PangaiaCBD run by an American company that operates in the Brazilian market as a dealer of cannabis-based products, the advertisement about the benefits of CBD draws attention.

Besides pointing to the substance as a natural painkiller capable of relieving pain, even in more serious cases such as cancer and fibromyalgia, the company says that CBD reduces symptoms of Alzheimer’s, epilepsy, and Parkinson’s disease and even improves sleep.

The studies on the use of cannabidiol for these diseases, however, are still of moderate or low quality. In addition, the indiscriminate use of the substance can present adverse effects and risks to the user.

On the other hand, the company also claims, on its site, that there are no side effects or contraindications regarding its simultaneous use with other drugs.

The tendentious propaganda worries specialists and anti-drug movements.

Another site that encourages medical treatment with cannabis is PangoCBD.

On the portal, the company does not hide its attempt to liberate the drug’s recreational use and even gives legal advice to those who wish to grow the plant.

An article on the site about the “cannabis market boom” says that “debureaucratization continues to be slow, and legalization of recreational use doesn’t seem close to happening. Either way, the wave is strong. Because while recreational use is not allowed, Brazilians find other opportunities to invest in the market.”

THERE IS NO ROBUST SCIENTIFIC EVIDENCE ABOUT THE BENEFITS OF CANNABIS

Several studies and the Brazilian Association of Psychiatry (ABP) itself have already pointed out that there is no definitive scientific evidence on the supposed benefits of the substance for most illnesses.

There are exceptions in cases cited by the Federal Council of Medicine (CFM), such as for patients with epileptic seizures related to Dravet, Doose, and Lennox-Gastaut syndromes.

In a new resolution restricting the use of cannabidiol, published last October, the CFM explained that the conclusions of studies are still fragile regarding the safety and efficacy of cannabidiol for the treatment of most diseases.

“The Council considers it prudent to await the progress of ongoing studies, avoiding exposing the population to situations of risk,” the CFM declared at the time.

In an interview with Gazeta do Povo, psychiatrist Ronaldo Laranjeira warned about the wide dissemination of false ideas about the medicinal use of marijuana, which disregards the most advanced scientific research.

“Marijuana is not magic, as if herb tea can make a patient better from a complex illness. That’s not how medicine works. Marijuana cannot be treated as a miracle drug that you make tea, and it will work. Medicine doesn’t work that way. It’s not safe for anyone to become a marijuana healer, and that’s what has been happening in Brazil,” he declared.

THE PROBLEMS WITH THE TERM “MEDICAL MARIJUANA”

Attorney Roberto Lásserre, national coordinator of the Brazil without Drugs Movement, regrets the approach used by some websites that, in his evaluation, are leading society into error.

“There is no such thing as medical marijuana. In Brazil, they are trying to get society to lower its guard so that in the near future, since ‘marijuana has medicinal effects,’ recreational use will be allowed. They are trying to lead society into error so that from then on they can ‘liberate generally’,” he says.

According to Brasserre, some judicial decisions have given “loopholes” for selling cannabis-based medicines.

He also cited a decision by the Superior Court of Justice (STJ) that guaranteed three people the possibility of growing marijuana plants to extract oil for their own use.

According to Brazilian legislation, the cultivation of the plant is a crime.

“It was an extremely badly worded decision to allow the planting of marijuana at home for medicinal purposes. And the worst thing is that many judges are making decisions of this type, opening precedents for a possible drug liberation,” explained the lawyer.

The court decisions, influenced by misinformation campaigns by companies interested in the drug’s liberation, contribute to increasing the circulation of clandestine extracts of homemade cannabidiol, many of which don’t work and can offer harmful side effects to those who consume them.

In Brazil, the National Health Surveillance Agency (Anvisa) has only released the importation of cannabidiol, and tetrahydrocannabinol (THC) extracts for manufacturing products in Brazil.

In 2019, the agency defined that these compounds would be marked with a black stripe due to the risk of dependence, increased tolerance (need to ingest increasing amounts to get the minimum desired effect), and intoxication.

The 20 products with these elements approved by the agency so far (they are not considered drugs due to lack of consolidated scientific evidence of effectiveness) need to be prescribed with a yellow (THC content less than 0.2%) or blue (THC content greater than 0.2%, higher risk) prescription.

The only medicine based on THC and cannabidiol approved to be imported in Brazil is Mevatyl, produced in the UK.

Anvisa approved it as an adjuvant medicine in treating spasticity in multiple sclerosis caused by damage or injury to the part of the central nervous system (brain or spinal cord) that controls voluntary movement.

MEDICINAL USE TO RELEASE RECREATIONAL USE

As pointed out by sources heard by the report, part of the supporters of the so-called “medical cannabis” use the medical use of marijuana flag to try to legalize the recreational use of the drug.

Lucas Gualtieri, a federal prosecutor and coordinator of the Special Action Group to Fight Crime (Gaeco) explains that although the diseases that can be treated with CBD are limited, companies that operate in the sector often take advantage of some medicinal properties to extend the so-called “recreational use” of marijuana.

“There is a distortion of the plant’s medicinal properties, leading to its use without the necessary controls for the protection of patients. The plant’s medicinal properties are used as a pretext to instill in society the idea that recreational use is harmless, which is not true, as demonstrated by consistent technical and scientific studies,” he declares.

“There are no safe means to control the doses of the active ingredient, and even the lack of control over the quality of the drug becomes a potential risk. I usually say that, didactically, defending the legalization of marijuana under the argument of medicinal purposes would be like defending the legalization of opium to enable the medicinal use of morphine,” he says.

Gazeta do Povo has already shown an enormous interest by the global financial market in marijuana.

According to an analysis by consultancy BDSA, published in March last year, global sales will grow 48% in 2020 compared to 2019, reaching US$21.3 billion.

The perspective is to reach 2026 at US$55.9 billion, representing an annual growth rate of around 17%.

In the National Congress, the marijuana lobby is trying at all costs to approve Bill 399/2015, which liberalizes activities such as cultivation, processing, storage, transport, industrialization, manipulation, and commercialization of marijuana-based products in the country and deals with the medicinal use of certain components of the plant.

The bill was approved by a special committee in the House of Representatives and awaits consideration in the House Plenary.

With information from Gazeta do Povo

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.